Transparency Market Research

Intravenous Immunoglobulin Market to Reach US$ 17,781.9 Mn by 2026


Albany, NY -- (SBWIRE) -- 12/26/2018 -- Global Intravenous Immunoglobulin Market - Snapshot

Immunoglobulins are highly purified, sterile specific medical therapy solutions containing gammaglobulin G (IgG) in a concentration of 95% or more. These are manufactured from highly refined pool of human plasma collected from at least 100 donors or more. Immunoglobulins can be administered through three different routes: intramuscular, intravenous, and subcutaneous. Intramuscular route of administration is a relatively older method and is not preferred currently, as it is painful. Intravenous immunoglobulin has emerged as a boon in the last few decades for patients with compromised immune system.

Browse Press Release @

The global intravenous immunoglobulin market continues to expand at a high growth rate. The market is driven by rise in global prevalence of autoimmune diseases such as primary humoral immunodeficiency (PIDD), multiple sclerosis, immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia, and Kawasaki syndrome. The global intravenous immunoglobulin market is projected to witness significant growth in the next few years due to technological advancements leading to development of new production and purification methods. Rapid increase in the number of neurological disorders, rise in the global geriatric population, and ever-increasing number of patients across the world have fueled demand for quick and reliable treatment measures. These factors have also driven usage of intravenous immunoglobulin for the treatment of off-label indications. Moreover, increase in investments in research and development of novel products by private and government bodies is likely to propel the market in the near future.

Request for Sample Copy of Report @

The global intravenous immunoglobulin market has been segmented based on indication, end-user, and region. In terms of indication, the market has been classified into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the global intravenous immunoglobulin market has been divided into hospitals, clinics, and home care. In terms of region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Request Report Brochure @

About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453